<DOC>
	<DOCNO>NCT01460381</DOCNO>
	<brief_summary>The study evaluate genetic profile respond LY2216684 effect Quinidine pharmacokinetics ( PK ) LY2216684 specific genetic profile . Side effect document .</brief_summary>
	<brief_title>A Study Evaluate Effect Genotype LY2216684</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Are overtly healthy male female , determine medical history physical examination Male participant : Agree use reliable method birth control study 1 month follow last dose study drug Female participant : Are woman childbearing potential test negative pregnancy time enrollment , use reliable method birth control ( include hormonal contraceptive ) 4 week prior administration study drug , agree use reliable method birth control study 1 month follow last dose study drug ; Are woman childbearing potential due surgical sterilization ( hysterectomy , bilateral oophorectomy , tubal ligation/occlusion ) menopause ( least 1 year without menses 6 month without menses follicle stimulate hormone [ FSH ] level &gt; 40 mIU/mL ) Have body weight &gt; 50 kg Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample per protocol Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly institutional review board ( IRB ) govern site Have normal blood pressure ( BP ) pulse rate ( PR ) ( sit position ) determine investigator Are predict cytochrome P450 ( CYP ) 2C19 extensive metabolizer ( EM ) poor metabolizer ( PM ) phenotype determine genotyping assessment Are predict CYP2D6 EM phenotype determine genotyping assessment . Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product ; concurrently enrol type medical research judge scientifically medically compatible study Have know allergies/intolerance LY2216684 quinidine , related compound , component formulation Are person previously receive investigational product study , complete withdrawn study study investigate LY2216684 within 6 month prior Screening . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have history show evidence significant active neuropsychiatric disease history suicide attempt ideation Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Intend use overthecounter prescription medication within 14 day prior dose study unless deem acceptable investigator Sponsor 's medical monitor . Exceptions include influenza vaccination , use topical medication ( provided evidence chronic dosing risk systemic exposure ) , occasional use acetaminophen/paracetamol/ibuprofen , hormone replacement therapy include thyroid replacement ( stable dose least 1 month ) . Have donate blood 500 mL within last month Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) , unwilling stop alcohol consumption 48 hour prior dose Period 1 Discharge ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) In opinion investigator sponsor , unsuitable inclusion study Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , participant unwilling stop caffeine consumption 48 hour prior dose Period 1 Discharge Have consume grapefruit grapefruitcontaining product 30 day prior enrollment unwilling abstain study Have document suspected history glaucoma Participants unwilling adhere smoke restriction Clinical Research Unit ( CRU ) resident CRU Use know inhibitor and/or inducer CYP2C19 CYP2D6 ( exception quinidine per protocol ) 30 day prior enrollment unwilling avoid study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>